Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227938 · ClinicalTrials.gov registry record · Phase 1
ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD
A Phase 1 study, sponsored by Alpine Immune Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04227938 is a Phase 1 study that was terminated before completion, run by Alpine Immune Sciences. The registered enrollment target is 1 participants.
The verdict
NCT04227938, a Phase 1 study, was terminated before completion, sponsored by Alpine Immune Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
Interventions
- DRUG ALPN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04227938
The ClinicalTrials.gov registry entry for NCT04227938 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpine Immune Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALPN-101 is the first listed.
NCT04227938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04227938 about?
NCT04227938 is a clinical study titled "ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD". The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
What is the current status of trial NCT04227938?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-05-11. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT04227938?
The interventions under investigation include: ALPN-101 (DRUG).
Who is sponsoring clinical trial NCT04227938?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.